Lakefront Biotherapeutics NV income statement

In fiscal 2025, Lakefront Biotherapeutics NV reported revenue of $1.26bn, up 321.6% on the year before, operating income of $334m (a 26.5% margin) and net income of $363m, or $5.51 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Lakefront Biotherapeutics NV: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	44	143	144	329	935	545	277	254	259	298	1,258
Cost of revenue	—	—	—	—	—	—	2	13	—	38	34
Gross profit	—	—	—	—	—	—	275	241	—	261	1,224
Research and development	144	155	247	374	470	598	379	284	261	363	519
Operating income	−99	−13	−101	−56	413	−204	−203	−138	−95	−204	334
Interest expense	0	0	1	1	1	11	14	7	2	1	1
Income before tax	−133	60	−131	−37	166	−353	−141	−75	6	−3	340
Income tax	−1	0	0	1	−0	1	2	1	10	−2	−21
Net income	−131	60	−131	−35	168	−349	−122	−230	229	80	363
Diluted EPS	−$3.68	$1.26	−$2.64	−$0.66	$2.79	−$5.35	−$1.87	−$3.50	$3.47	$1.21	$5.51
Diluted shares (average)	36m	47m	49m	52m	58m	65m	66m	66m	66m	66m	66m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: LKFT vs MDGL LKFT vs PTCT ACAD vs LKFT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lakefront Biotherapeutics NV's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lakefront Biotherapeutics NV.